News

BIO-CAT Grows in Zion Crossroads

BIO-CAT, Inc., a biotechnology company that specializes in enzymes and other advanced microbial solutions, plans to add at least 30,000 square feet to its fermentation facilities in Zion Crossroads. The expansion is projected to start in 2022. The company will add several new jobs and is considering building another 30,000-square-foot section in a second phase.

“Louisa County has partnered with BIO-CAT from the very beginning – they understand not only the economic value that [we bring] to the county, but the overall benefit this expansion can bring to the local community,” said Stephen Schuler, associate vice president of operations.

“It is very rewarding to witness a Louisa business and industry leader grow and thrive locally to meet the demands of their global customers,” said Bob Babyok, Louisa County Board of Supervisors chairman (Green Springs District).

“Similar to brewing and distilling fermentation processes, microbial fermentation can be costly; it requires substantial customization of both building design and equipment. Custom fermentation tanks, stainless steel piping, centrifuges, spray dryers, storage tanks and other unique equipment will be installed at the site, all of which require federal Food and Drug Administration oversight and regular inspections.

“Whether developing beneficial bacteria like probiotics for the human digestive system and production animal feed or developing the right strains to amend the soil microbiome for agriculture, we are developing amazing proprietary solutions for the future,” BIO-CAT Chief Executive Officer and Co-Founder Chris Schuler said.

“BIO-CAT’s financial commitment in this expansion and creation of new job opportunities for our citizens is critical to local economic growth and success,” said Supervisor Fitzgerald Barnes, who represents the Patrick Henry District where the company is located.

BIO-CAT recently celebrated 33 years of industry leadership, during the same year that the company lost its co-founder, Ed Schuler, at the age of 89. Ed, his son Chris and partner Brian Huffman founded the company in 1988.

The firm has doubled its business every five years and is involved in human nutrition, animal nutrition, and crop science. As the company’s revenue has grown, so has its presence in Louisa County. What started as a 12,000-square-foot building has since expanded to over 90,000 square feet.

In 2005, Chris Schuler decided to expand the business portfolio from a pure focus on enzymes, to producing and fermenting probiotics, via an acquisition of a biotech company in Minnesota. After 15 years of success in Minnesota, the company plans to expand that business through the expansion in Zion Crossroads.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …